Oncotelic Therapeutics, Inc. (OTLC)

Oncotelic Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	0.07	-	-	1.74
Gross Profit	-	0.07	-	-	1.74
Selling, General & Admin	0.38	0.57	4.85	5.47	5.02
Research & Development	-	0.06	0.76	3.66	4.3
Operating Expenses	0.38	0.63	5.61	9.13	9.33
Operating Income	-0.38	-0.56	-5.61	-9.13	-7.58
Interest Expense	-0.86	-1.04	-2.97	-2	-2
Other Non Operating Income (Expenses)	-0.26	-0.15	0.68	0.29	-0.05
EBT Excluding Unusual Items	-1.49	-1.76	-7.91	-10.84	-9.63
Impairment of Goodwill	-3.2	-6.08	-4.11	-	-
Gain (Loss) on Sale of Investments	-	0.01	-	-	-
Gain (Loss) on Sale of Assets	-	-	16.95	-	-
Other Unusual Items	-0.09	-0.37	-0.26	0.32	-0.34
Pretax Income	-4.78	-8.21	4.68	-10.52	-9.97
Earnings From Continuing Operations	-4.78	-8.21	4.68	-10.52	-9.97
Minority Interest in Earnings	0.26	0.3	0.42	1.13	0.47
Net Income	-4.52	-7.9	5.09	-9.39	-9.5
Net Income to Common	-4.52	-7.9	5.09	-9.39	-9.5
Shares Outstanding (Basic)	404	384	384	303	88
Shares Outstanding (Diluted)	404	384	457	303	88
Shares Change (YoY)	5.29%	-16.01%	50.89%	244.02%	46.94%
EPS (Basic)	-0.01	-0.02	0.01	-0.03	-0.11
EPS (Diluted)	-0.01	-0.02	0.01	-0.03	-0.11
Gross Margin	-	100.00%	-	-	100.00%
Operating Margin	-	-806.96%	-	-	-435.69%
Profit Margin	-	-11290.13%	-	-	-545.86%
EBITDA	-	-0.55	-5.6	-9.06	-7.22
D&A For EBITDA	-	0.01	0.01	0.06	0.36
EBIT	-0.38	-0.56	-5.61	-9.13	-7.58
Revenue as Reported	-	0.07	-	-	1.74

Updated Nov 19, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.